培美曲塞或吉西他滨联合顺铂治疗晚期肺腺癌临床对比研究

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Adenocarcinoma of Lung

目的:探究培美曲塞或吉西他滨联合顺铂治疗晚期肺腺癌的临床效果,并评估这两种化疗方案的副反应发生率。方法:将120例晚期肺腺癌患者按随机数表法分为两组:实验组和对照组各60例。统计临床治疗效果、副反应。结果:实验组和对照组在两个化疗疗程后其缓解率为51.67%和41.67%,其差异不存在统计学意义(P>0.05),同时,副反应白细胞降低及低血红蛋白血症发生率实验组低于对照组[58.3%vs 76.7%,50.0%vs 68.3%]。结论:培美曲塞或吉西他滨联合顺铂治疗晚期肺腺癌的临床疗效相同,但培美曲塞联合顺铂化疗的不良反应比较低,患者更易接受。

Objective: To evaluate the efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in thetreatment of patients with advanced adenocarcinoma of lung,and assess the rate of side effect of these 2 chemotherapy regimens.Methods:A total of 120 patients with advanced adenocarcinoma of lung were randomly assigned to 2 groups according to therandom number table method:the experiment group(n=60) and the control group(n=60).The treatment cycle were both onceevery three weeks.The curative effects,side effects.Results:The total clinical effective after 2 treatment cycles in experimentalgroup and the control group were 51.67%(31/60) and 41.67%(23/60),and it is no different between that 2 groups (P>0.05).The rates of leukopenia and lower hemoglobin were different between 2 groups [58.3%(35/60) vs 76.7%(46/60),50.0%(30/60)vs 68.3%(41/60)].Conclusion:The efficacy of pemetrexed and gemcitabine combined with cisplatin in the treatment of patientswith advanced adenocarcinoma of lung were same.But the rates of the side effects of pemetrexed with cisplatin were lower thangemcitabine.